ANTX - AN2 Therapeutics Inc

5.46
0.210   3.846%

Share volume: 4,201,527
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$5.25
0.21
0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 35%
Dept financing 20%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
91.58%
1 Month
396.36%
3 Months
358.82%
6 Months
329.92%
1 Year
301.47%
2 Year
85.08%
Key data
Stock price
$5.46
P/E Ratio 
0.00
DAY RANGE
$4.25 - $5.53
EPS 
-$1.34
52 WEEK RANGE
$1.00 - $6.91
52 WEEK CHANGE
$304.44
MARKET CAP 
34.704 M
YIELD 
N/A
SHARES OUTSTANDING 
27.402 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
2.88
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$10,161,685
AVERAGE 30 VOLUME 
$3,436,446
Company detail
CEO: Eric Easom
Region: US
Website: an2therapeutics.com
Employees: 20
IPO year: 2022
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

AN2 Therapeutics is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Recent news